Abstract: The present invention provides mutant RSV F molecules, such as those that can be, or are stabilized, in a pre-fusion conformation by the introduction of one or more DT cross-links. The present invention also provides methods of making such mutant RSV F molecules, compositions comprising such mutant RSV F molecules, and methods of use of such mutant RSV F molecules, for example in vaccination methods, therapeutic methods, and antibody production methods.
Type:
Grant
Filed:
August 7, 2018
Date of Patent:
March 8, 2022
Inventors:
Christopher Marshall, Mark Yondola, Roberto Mariani, Aaron Zomback, Sonal Gidwani
Abstract: The present invention relates to immunogenic compositions comprising RSV F protein, methods for preparing compositions that contain RSV F protein ecto-domain polypeptides, and to certain engineered RSV F proteins and nucleic acids that encode the engineered RSV F proteins. Compositions prepared using the methods can contain RSV F protein ecto-domain polypeptides in a predominant or single desired form and conformation. The invention also relates to methods for inducing an immune response to RSV F.
Abstract: This disclosure relates to chimeric respiratory syncytial virus (RSV), live attenuated vaccine and immunogenic compositions, and methods of use. In certain embodiments, the chimeric respiratory syncytial virus has a mutated gene pattern encoding an RSV F protein having M at position 79, R at position 191, K at position 357, and/or Y at position 371.
Abstract: Compositions, vaccines and methods using adenovirus vectors for inducing protective immunity against a respiratory syncytial virus (RSV) infection are described.
Type:
Grant
Filed:
May 15, 2018
Date of Patent:
January 25, 2022
Assignee:
Janssen Vaccines & Prevention B.V.
Inventors:
Olivier Godeaux, Jerald C. Sadoff, Macaya Julie Douoguih
Abstract: Aptamers have been identified that bind to the sGP protein in ebola virus. The aptamers are single stranded DNA aptamers. The aptamers have high specificity and bind sGP in serum samples. The aptamers can be used to detect infection of individuals with ebola virus. Methods for detecting ebola virus in an individual are disclosed.
Abstract: Methods of inducing a safe immune response against respiratory syncytial virus (RSV) in a human subject in need thereof, including administering to the subject a composition including recombinant adenovirus including a nucleic acid encoding an RSV Fusion (F) protein including the amino acid sequence of SEQ ID NO: 1, and a pharmaceutically acceptable carrier, in a total dose of from about 1×1010 to about 2×1011 viral particles (vp), are described.
Type:
Grant
Filed:
September 13, 2018
Date of Patent:
January 25, 2022
Assignee:
Janssen Vaccines & Prevention B.V.
Inventors:
Myra Noorely Widjojoatmodjo, Olivier Godeaux, Kristi Lynn Williams, Benoit Christophe Stephan Callendret, Jerald C. Sadoff
Abstract: This invention relates to SARS-CoV-2 viruses adapted with nanoluciferase reporter molecules and mouse-adapted SARS-CoV-2 viruses, compositions including the same and methods of use thereof.
Type:
Grant
Filed:
February 11, 2021
Date of Patent:
January 18, 2022
Assignee:
The University of North Carolina at Chapel Hill
Inventors:
Ralph Baric, Kenneth Harold Dinnon, III, Sarah Rebecca Leist
Abstract: Provided is an isolated mammalian negative strand RNA virus, metapneumovirus (MPV), within the sub-family Pneumoviridae, of the family Paramyxoviridae. Also provided are isolated mammalian negative strand RNA viruses identifiable as phylogenetically corresponding or relating to the genus Metapneumovirus and components thereof. In particular, provided is a mammalian MPV, subgroups and variants thereof. Also provided are genomic nucleotide sequences of different isolates of mammalian MPV, in particular, human MPV. Disclosed is the use of the sequence information of different isolates of mammalian MPV for diagnostic and therapeutic methods. Provided are nucleotide sequences encoding the genome of an MPV or a portion thereof, including both mammalian and avian MPV. Further described are chimeric or recombinant viruses encoded by the nucleotide sequences and chimeric and recombinant mammalian MPV that comprise one or more non-native or heterologous sequences.
Type:
Grant
Filed:
June 3, 2020
Date of Patent:
January 11, 2022
Assignee:
Erasmus University Medical Center Rotterdam
Inventors:
Ronaldus Adrianus Maria Fouchier, Bernadetta Gerarda Van Den Hoogen, Albertus Dominicus Marcellinus Erasmus Osterhaus, Jan Cornelius De Jong, Jan Groen
Abstract: The present disclosure provides recombinantly manufactured fusion proteins comprising a SARS-CoV-2 Receptor Binding Domain (SARS-CoV-2-RBD) fragment or an analog thereof linked to a human Fc fragment for use in relation to the 2019 Novel Coronavirus (COVID-19). Embodiments include the administration of the fusion proteins to patients that have recovered from COVID-19 as a booster vaccination, to antibody naïve patients to produce antibodies to the SARS-CoV-2 virus to enable the patients to become convalescent plasma donors, to patients who have been infected by the SARS-CoV-2 virus and have contracted COVID-19 in order to limit the scope of the infection and ameliorate the disease, and as a prophylactic COVID-19 vaccine. Exemplary Fc fusion proteins and pharmaceutical formulations of exemplary Fc fusion proteins are provided, in addition to methods of use and preparation.
Type:
Grant
Filed:
April 9, 2021
Date of Patent:
January 4, 2022
Assignee:
Akston Biosciences Corporation
Inventors:
Todd C. Zion, Thomas M. Lancaster, Thillainayagam Sathiyaseelan, Kexin Huang
Abstract: The invention provides a composition useful to prepare high titer influenza B viruses, e.g., in the absence of helper virus, which includes internal genes from an influenza B virus vaccine strain or isolate, e.g., one that is safe in humans, for instance, one that does not result in significant disease, that confer enhanced growth in cells in culture, such as MDCK cells, or in eggs.
Type:
Grant
Filed:
February 17, 2017
Date of Patent:
December 14, 2021
Assignee:
Wisconsin Alumni Research Foundation (WARF)
Abstract: This application provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, as well as means and methods for producing them.
Type:
Grant
Filed:
May 1, 2020
Date of Patent:
November 30, 2021
Assignee:
MEDIMMUNE, LLC
Inventors:
Nancy Ulbrandt, Nicole Kallewaard-Lelay, Andy Q. Yuan, Bettina Richter
Abstract: The invention relates to antibodies and antigen binding fragments thereof that are capable of binding to influenza B virus hemagglutinin (HA) and neutralizing influenza B virus in two phylogenetically distinct lineages. In one embodiment, the antibody or antigen binding fragment is capable of binding to influenza B virus hemagglutinin and neutralizing influenza B virus in Yamagata and Victoria lineages.
Type:
Grant
Filed:
November 7, 2019
Date of Patent:
November 16, 2021
Assignees:
MEDIMMUNE, LLC, HUMABS BIOMED SA
Inventors:
Nicole Kallewaard-Lelay, Qing Zhu, Ebony Benjamin, Leslie Wachter, Andy Yuan, Josephine Mary McAuliffe, Davide Corti, Antonio Lanzavecchia
Abstract: Embodiments of a recombinant Respiratory Syncytial Virus (RSV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the RSV F ectodomain trimer and methods of producing the RSV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the recombinant RSV F ectodomain trimer to the subject.
Type:
Grant
Filed:
March 29, 2017
Date of Patent:
November 16, 2021
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services
Inventors:
Peter Kwong, Barney Graham, John Mascola, Li Ou, Aliaksandr Druz, Man Chen, Wing-Pui Kong, Ivelin Stefanov Georgiev, Emily Rundlet, Michael Gordon Joyce, Yaroslav Tsybovsky, Paul Thomas, Marie Pancera, Mallika Sastry, Cinque Soto, Joseph Van Galen, Guillaume Stewart-Jones, Yongping Yang, Baoshan Zhang, Ulrich Baxa
Abstract: The invention relates to the field of virology. The invention provides an isolated essentially mammalian negative-sense single-stranded RNA virus (MPV) within the subfamily Pneumovirinae of the family Paramyxoviridae and identifiable as phylogenetically corresponding to the genus Metapneumovirus and components thereof.
Type:
Grant
Filed:
December 30, 2019
Date of Patent:
November 2, 2021
Assignee:
Erasmus University Medical Center Rotterdam
Inventors:
Jan Cornelius De Jong, Ronaldus Adrianus Maria Fouchier, Bernadetta Gerarda Van Den Hoogen, Albertus D. M. E. Osterhaus, Jan Groen
Abstract: Stable pre-fusion respiratory syncitial virus (RSV) F proteins (or fragment thereof) are described. Compositions containing the proteins and uses of the compositions for the prevention and/or treatment of RSV infection are also described.
Type:
Grant
Filed:
April 4, 2017
Date of Patent:
October 26, 2021
Assignee:
Janssen Vaccines & Prevention B.V.
Inventors:
Anders Krarup, Johannes Petrus Maria Langedijk
Abstract: A method for producing a transgenic cell, may include contacting, in vitro, (i) a virus comprising: a chimeric protein of an antibody-binding protein and a vesicular stomatitis virus G (VSV-G) protein; and a foreign gene, with (ii) a target cell and an antibody specific to the target cell, and/or a target cell comprising a membrane antibody, to infect the target cell with the virus.
Abstract: Disclosed are Respiratory Syncytial Virus (RSV) antigens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the antigens and methods of producing the antigens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the antigen to the subject.
Type:
Grant
Filed:
July 2, 2018
Date of Patent:
September 28, 2021
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services
Inventors:
Peter D. Kwong, Barney S. Graham, Jason S. McLellan, Jeffrey Boyington, Lei Chen, Man Chen, Gwo-Yu Chuang, Ivelin Stefanov Georgiev, Jason Gorman, Michael Gordon Joyce, Masaru Kanekiyo, Gilad Ofek, Marie Pancera, Mallika Sastry, Cinque Soto, Sanjay Srivatsan, Guillaume Stewart-Jones, Yongping Yang, Baoshan Zhang, Tongqing Zhou
Abstract: In some embodiments the present invention provides influenza hemagglutinin (“HA”) polypeptides, proteins, and protein complexes that comprise a stalk domain that is engineered to facilitate maintenance of its native trimeric conformation, even if the head domain of the HA protein is removed or disrupted. In some embodiments, the present invention provides compositions comprising such polypeptides, proteins, and protein complexes, and methods of use of such proteins and compositions, for example as vaccine immunogens.
Type:
Grant
Filed:
December 22, 2017
Date of Patent:
September 28, 2021
Assignee:
Calder Biosciences Inc.
Inventors:
Christopher Patrick Marshall, Peter Joseph Alff, Claudio Bertuccioli, Mark Andrew Yondola
Abstract: The invention relates to a method for determining the cell mediated immune competence of a subject. The method comprises conducting a cell-mediated immunoassay (CMI) on a sample comprising immune cells from a subject. The method further comprises detecting in vitro an immune response to a pool of peptides, wherein the pool of peptides is derived from at least three viral antigens.